Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

RCKT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Rocket Pharmaceuticals, Inc.NASDAQ: RCKT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $2.15M fell 28.2% year over year, behind the +1.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -28.2% toward the trailing-twelve-month pace of +1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.15M-3.2% QoQ
Last fiscal yearDec 2025
$11.03M+17.6% YoY
LTMMar 2026
$10.18M+1.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.2%——
1 year+17.6%——
3-year CAGR+20.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
11.03M USD
Year-over-year change
+17.6%
4-year CAGR
+19.7%

Depreciation & Amortization vs competitors

How RCKT compares with its peers on the latest reported figures

  • RCKT's LTM Mar 2026 depreciation & amortization of $10.18M is the 3rd highest of the 10 companies compared; the peer median is $1.62M.
  • Its year-over-year change of +1.0% is the 7th highest of 9, against a peer median of +15.5%.
  • Over three fiscal years its annual growth of +20.7% compares with a peer median of +9.8%.
RCKT Competitors Peer median
Depreciation & Amortization for RCKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$13M +24.1%+9.8%14.0%
DBVTDBV Technologies S.A.LTM Mar 2026$12.36M +53.3%-27.5%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$10.18M +1.0%+20.7%—
QSIQuantum-Si incorporatedLTM Mar 2026$4.76M +6.9%+19.9%257.1%
ANNXAnnexon, Inc.LTM Mar 2026$3.06M +36.2%+7.2%—
SLDBSolid Biosciences Inc.LTM Mar 2026$1.62M -35.9%-12.1%—
AURAAura Biosciences, Inc.LTM Mar 2026$1.13M -6.8%-1.4%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$620K +1.3%+10.1%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$325.5K —+443.4%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$55K +44.7%+18.3%—
Peer median (excluding RCKT) $1.62M+15.5%+9.8%135.6%

Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000011.03M
Gross Profit0000(11.03M)
Gross Margin—————
Research & Development125.48M165.57M186.34M171.24M142.02M
Selling, General & Admin41.77M58.77M73.32M101.96M86.5M
Operating Expenses167.25M224.34M259.66M273.21M217.49M
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
EBITDA(157.81M)(213.69M)(236.62M)(247.49M)(210.21M)
EBITDA Margin—————
Operating Income(167.25M)(224.34M)(259.66M)(273.21M)(228.52M)
Operating Margin—————
Interest Income3.07M3.89M15.94M18.22M10.62M
Interest Expense5.89M1.91M1.88M1.89M1.89M
Other Income / Expenses(1.82M)2.48M14.06M14.46M5.39M
Income Before Tax(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Net Margin—————
EPS (Basic)(2.68)(3.26)(2.92)(2.73)(2.01)
EPS (Diluted)(2.68)(3.26)(2.92)(2.73)(2.01)
Weighted Avg Shares63.24M68.15M84.01M94.81M111.12M
Weighted Avg Shares (Diluted)63.24M68.15M84.01M94.81M111.12M

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.